Epigenetics, microRNAs, and carcinogenesis: Functional role of microRNA-137 in uveal melanoma

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 3, 2011, Pages 1193-1199

  Chen, Xiaoyan ^a,b   Wang, Jiao ^a,b   Shen, Huanjun ^a,b   Lu, Juan ^a,b   Li, Canxia ^a,b   Hu, Dan Ning ^b,c   da Dong, Xiang ^d   Yan, Dongsheng ^a,b   Tu, Lili ^a,b  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b Key Laboratory of Vision Science   (China)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d STAMFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CELL CYCLE REGULATORY PROTEIN; CYCLIN DEPENDENT KINASE 6; LUCIFERASE; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MICRORNA; MICRORNA 137; REGULATOR PROTEIN; SCATTER FACTOR RECEPTOR; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ARTICLE; BIOINFORMATICS; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; EPIGENETICS; GENE IDENTIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UVEA MELANOMA; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL CYCLE; CELL CYCLE PROTEINS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 6; DOWN-REGULATION; EPIGENOMICS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; MICRORNAS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; UVEAL NEOPLASMS;

EID: 79955942571     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-5272     Document Type: Article

References (39)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, andfunction. Cell. 2004;116:281-297.
2. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843-854.
3. Ruvkun G. The perfect storm of tiny RNAs. Nat Med. 2008;14: 1041-1045.
4. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99:15524-15529.
5. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10:704-714.
6. Skaftnesmo KO, Prestegarden L, Micklem DR, Lorens JB. MicroRNAs in tumorigenesis. Curr Pharm Biotechnol. 2007;8:320-325.
7. Yan D, Zhou X, Chen X, et al. MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met. Invest Ophthalmol Vis Sci. 2009;50:1559-1565.
8. Gillanders E, Juo SH, Holland EA, et al. Localization of a novel melanoma susceptibility locus to 1p22. Am J Hum Genet. 2003; 73:301-313.
9. Bemis LT, Chen R, Amato CM, et al. MicroRNA-137 targets microphthalmia- associated transcription factor in melanoma cell lines. Cancer Res. 2008;68:1362-1368.
10. Levy C, Khaled M, Fisher DE. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med. 2006;12: 406-414.
11. Soulieres D, Rousseau A, Deschenes J, Tremblay M, Tardif M, Pelletier G. Characterization of gangliosides in human uveal melanoma cells. Int J Cancer. 1991;49:498-503.
12. Hu DN, McCormick SA. Biochemical pathways: different gene expression and cellular pathways determining tumor phenotype comparison of uveal melanocytes and uveal melanoma cells. In: Albert DM, Polans A, eds. Ocular Oncology. New York: Marcel Dekker; 2003;189-210.
13. Hu DN, McCormick SA, Ritch R, Pelton-Henrion K. Studies of human uveal melanocytes in vitro: isolation, purification and cultivation of human uveal melanocytes. Invest Ophthalmol Vis Sci. 1993;34:2210-2219.
14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(Δ Δ-C(T)) method. Methods. 2001;25:402-408.
15. Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res. 2008;68:2094-2105.
16. Silber J, Lim DA, Petritsch C, et al. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med. 2008;6:14.
17. Takaki T, Fukasawa K, Suzuki-Takahashi I, et al. Preferences for phosphorylation sites in the retinoblastoma protein of D-type cyclin-dependent kinases, Cdk4 and Cdk6, in vitro. J Biochem. 2005;137:381-386.
18. Meyerson M, Harlow E. Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol. 1994;14:2077-2086.
19. Lujambio A, Calin GA, Villanueva A, et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A. 2008;105:13556-13561.
20. Datta J, Kutay H, Nasser MW, et al. Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res. 2008;68:5049-5058.
21. Lujambio A, Ropero S, Ballestar E, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res. 2007;67:1424-1429.
22. Costello JF, Plass C. Methylation matters. J Med Genet. 2001;38: 285-303.
23. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene. 2002;21:5427-5440.
24. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042-2054.
25. Schultz J, Lorenz P, Gross G, Ibrahim S, Kunz M. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res. 2008;18:549-557.
26. Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005;436:117-122.
27. Mouriaux F, Vincent S, Kherrouche Z, et al. Microphthalmia transcription factor analysis in posterior uveal melanomas. Exp Eye Res. 2003;76:653-661.
28. McGill GG, Haq R, Nishimura EK, Fisher DE. c-Met expression is regulated by Mitf in the melanocyte lineage. J Biol Chem. 2006; 281:10365-10373.
29. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4:915-925.
30. Otsuka T, Takayama H, Sharp R, et al. c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Cancer Res.1998;58:5157-5167.
31. Puri N, Ahmed S, Janamanchi V, et al. c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res. 2007;13:2246-2253.
32. Economou MA, All-Ericsson C, Bykov V, et al. Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications. Invest Ophthalmol Vis Sci. 2005;46:4372-4375.
33. Abdel-Rahman MH, Boru G, Massengill J, Salem MM, Davidorf FH. MET oncogene inhibition as a potential target of therapy for uveal melanomas. Invest Ophthalmol Vis Sci. 2010;51:3333-3339.
34. Du J, Widlund HR, Horstmann MA, et al. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell. 2004;6:565-576.
35. Tang L, Li G, Tron VA, Trotter MJ, Ho VC. Expression of cell cycle regulators in human cutaneous malignant melanoma. Melanoma Res. 1999;9:148-154.
36. Grossel MJ, Hinds PW. From cell cycle to differentiation: an expanding role for cdk6. Cell Cycle. 2006;5:266-270.
37. Hausler T, Stang A, Anastassiou G, et al. Loss of heterozygosity of 1p in uveal melanomas with monosomy 3. Int J Cancer. 2005;116:909-913.
38. Kilic E, Naus NC, van Gils W, et al. Concurrent loss of chromosome arm 1p and chromosome 3 predicts a decreased disease-free survival in uveal melanoma patients. Invest Ophthalmol Vis Sci. 2005;46:2253-2257.
39. Aalto Y, Eriksson L, Seregard S, Larsson O, Knuutila S. Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42:313-317.